Dong-A ST launches Stelara biosimilar 'Imyuldosa' in the US

[Financial News] Dong-A ST announced on the 19th that it has launched the Stelara biosimilar 'Imyuldosa (active ingredient Ustekinumab)' in the United States through its partners, the multinational pharmaceutical companies Intas and Accord Biopharma.
Imyuldosa is a biosimilar of Stelara developed by Janssen and is a treatment for inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara is a global blockbuster drug that sold approximately 29 trillion won last year.
Imyuldosa has been launched in a total of 14 countries, including Germany, the United Kingdom, and Spain, and has obtained product approval in the Middle East and North Africa (MENA) region, including Saudi Arabia, Qatar, and the United Arab Emirates.
A representative from Dong-A ST stated, "With the launch of Imyuldosa in the US following Europe, the pace of global market entry is accelerating," and "We will do our best to establish Imyuldosa as an effective treatment option for patients worldwide."
Meanwhile, Imyuldosa has been jointly developed by Dong-A Socio Holdings and Meiji Seika Pharma since 2013, and in July 2020, the rights for development and commercialization were transferred to Dong-A ST for efficient global project execution, with Dong-A ST and Meiji Seika Pharma continuing joint development.
In July 2021, a global license-out agreement for Imyuldosa was signed with the multinational pharmaceutical company Intas. Intas is commercializing Imyuldosa through its global affiliates, including Accord Biopharma in the US and Accord Healthcare in Europe, the UK, and Canada.



vrdw88@fnnews.com Kang Joong-mo Reporter